Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview
Dermata Therapeutics Inc <DRMA.OQ> expected to post a loss of 55 cents a share - Earnings Preview
Dermata Therapeutics Inc DRMA.OQ DRMA.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Dermata Therapeutics Inc is for a loss of 55 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Dermata Therapeutics Inc is $4.00, about 260.4% above its last closing price of $1.11
This summary was machine generated August 7 at 20:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Dermata Therapeutics
See all newsNASDAQ RESUMED AT 10:31 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM
Brief: Dermata Therapeutics - To Launch First Commercial Product Tome Foundational Treatment On August 25, 2026
Dermata Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview